JP2004528364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528364A5 JP2004528364A5 JP2002586949A JP2002586949A JP2004528364A5 JP 2004528364 A5 JP2004528364 A5 JP 2004528364A5 JP 2002586949 A JP2002586949 A JP 2002586949A JP 2002586949 A JP2002586949 A JP 2002586949A JP 2004528364 A5 JP2004528364 A5 JP 2004528364A5
- Authority
- JP
- Japan
- Prior art keywords
- methyleneandrost
- pharmaceutical composition
- compound
- give
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- JMCNUPJJRLUBQN-JZCOGDJRSA-N (3R,8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound O[C@@H]1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 JMCNUPJJRLUBQN-JZCOGDJRSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- JMCNUPJJRLUBQN-SIRBJWHBSA-N (3S,8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound O[C@H]1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 JMCNUPJJRLUBQN-SIRBJWHBSA-N 0.000 claims 2
- QXEURENTQIAFIS-FSGKZVOOSA-N (8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 QXEURENTQIAFIS-FSGKZVOOSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000005466 alkylenyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- CDCQHKMEOJJEBD-SIRBJWHBSA-N (3S,8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CC=C21 CDCQHKMEOJJEBD-SIRBJWHBSA-N 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 238000006751 Mitsunobu reaction Methods 0.000 claims 1
- 210000001121 Vomeronasal Organ Anatomy 0.000 claims 1
- 238000007239 Wittig reaction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- XQTIWNLDFPPCIU-UHFFFAOYSA-N cerium(3+) Chemical class [Ce+3] XQTIWNLDFPPCIU-UHFFFAOYSA-N 0.000 claims 1
- 229940119350 dehydroepiandrosterone Drugs 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 230000001590 oxidative Effects 0.000 claims 1
- 229960002847 prasterone Drugs 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 claims 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (15)
- 疾患はうつ病である、請求項1記載の医薬組成物。
- 化合物は17−メチレンアンドロスタ−4−エン−3α−オールである、請求項1記載の医薬組成物。
- 化合物はプレグナ−17(20)Z−エン−3α−オールである、請求項1記載の医薬組成物。
- 有効な量は20pg〜20ngである、請求項1記載の医薬組成物。
- 有効な量は200pg〜2ngである、請求項4記載の医薬組成物。
- 疾患はうつ病である、請求項7記載の医薬品。
- 化合物は17−メチレンアンドロスタ−4−エン−3α−オールである、請求項7記載の医薬品。
- 化合物はプレグナ−17(20)Z−エン−3α−オールである、請求項7記載の医薬品。
- 有効な量は20pg〜20ngである、請求項7記載の医薬品。
- 有効な量は200pg〜2ngである、請求項11記載の医薬品。
- 17−メチレンアンドロスタ−4−エン−3α−オールの製造法であって、
(a)17−メチレンアンドロスタ−4−エン−3β−オールをミツノブ反応条件下で処理して、17−メチレンアンドロスタ−4−エン−3α−オールのエステルを得て;そして、
(b)該エステルを加水分解して、17−メチレンアンドロスタ−4−エン−3α−オールを得る、
ことを含む、該製造法。 - 17−メチレンアンドロスタ−4−エン−3β−オールを、
(a)デヒドロエピアンドロステロンをウィッティヒ反応条件下で処理して、17−メチレンアンドロスタ−5−エン−3β−オールを得て;
(b)該17−メチレンアンドロスタ−5−エン−3−β−オールを酸化および単離して、17−メチレンアンドロスタ−4−エン−3−オンを得て;そして、該17−メチレンアンドロスタ−4−エン−3−オンを還元して、17−メチレンアンドロスタ−4−エン−3−β−オールを得る、
ことによって製造する、請求項13記載の製造法。 - 17−メチレンアンドロスタ−4−エン−3−オンを、セリウム(III)塩の存在下で水素化ホウ素ナトリウムを用いて還元する、請求項14記載の製造法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/848,247 US20030045514A1 (en) | 2001-05-03 | 2001-05-03 | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors |
PCT/US2002/013255 WO2002089814A1 (en) | 2001-05-03 | 2002-04-26 | 17-METHYLENE-ANDROSTAN-3α-OL ANALOGS AS CRH INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004528364A JP2004528364A (ja) | 2004-09-16 |
JP2004528364A5 true JP2004528364A5 (ja) | 2005-12-22 |
Family
ID=25302777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002586949A Pending JP2004528364A (ja) | 2001-05-03 | 2002-04-26 | CRHインヒビターとしての17−メチレンアンドロスタン−3α−オールアナログ |
Country Status (8)
Country | Link |
---|---|
US (2) | US20030045514A1 (ja) |
EP (1) | EP1392320B1 (ja) |
JP (1) | JP2004528364A (ja) |
CA (1) | CA2484596A1 (ja) |
DE (1) | DE60217480T2 (ja) |
ES (1) | ES2278962T3 (ja) |
MX (1) | MXPA03010055A (ja) |
WO (1) | WO2002089814A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2571440A1 (en) * | 2004-06-29 | 2006-01-12 | Jadolabs Gmbh | Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
JP5524177B2 (ja) | 2008-04-09 | 2014-06-18 | フェリン ファーマシューティカルズ インコーポレイテッド | ほてりのためのステロイド治療 |
WO2009141110A1 (de) * | 2008-05-21 | 2009-11-26 | Grünenthal GmbH | Verfahren zur selektiven synthese von 3-alpha-hydroxychlormadinonacetat |
US20120214987A1 (en) * | 2010-12-15 | 2012-08-23 | Yu Ge | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
CN103764151B (zh) | 2011-05-20 | 2017-05-17 | 国家医疗保健研究所 | Cb1受体拮抗剂 |
US10259839B2 (en) | 2012-11-28 | 2019-04-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone |
AU2013371025B2 (en) | 2012-12-28 | 2018-01-18 | Pherin Pharmaceuticals, Inc. | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders |
WO2019169113A1 (en) * | 2018-03-02 | 2019-09-06 | Ponce Medical School Foundation, Inc. | Compositions and methods for the treatment of endometriosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969168A (en) * | 1991-01-07 | 1999-10-19 | Pherin Corporation | Androstanes for inducing hypothalamic effects |
US6057439A (en) * | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
US5994333A (en) * | 1994-08-04 | 1999-11-30 | Pherin Corporation | Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
GB9626746D0 (en) * | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
-
2001
- 2001-05-03 US US09/848,247 patent/US20030045514A1/en not_active Abandoned
-
2002
- 2002-04-26 EP EP02769291A patent/EP1392320B1/en not_active Expired - Lifetime
- 2002-04-26 ES ES02769291T patent/ES2278962T3/es not_active Expired - Lifetime
- 2002-04-26 DE DE60217480T patent/DE60217480T2/de not_active Expired - Lifetime
- 2002-04-26 CA CA002484596A patent/CA2484596A1/en not_active Abandoned
- 2002-04-26 JP JP2002586949A patent/JP2004528364A/ja active Pending
- 2002-04-26 WO PCT/US2002/013255 patent/WO2002089814A1/en active IP Right Grant
- 2002-04-26 MX MXPA03010055A patent/MXPA03010055A/es active IP Right Grant
-
2003
- 2003-06-13 US US10/461,788 patent/US20030220309A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1212834C (zh) | 氟西汀肠溶微丸 | |
EP1945224B1 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
JP2007512376A5 (ja) | ||
JPH09504543A (ja) | 白内障の予防法及び予防手段 | |
JP2005513023A5 (ja) | ||
CN1522145A (zh) | 用于治疗外阴阴道炎和阴道病的含有抗真菌剂组合物 | |
CN1239427A (zh) | Mupirocin在制备用于治疗与病原生物体鼻咽建群有关的细菌感染的药物中的应用 | |
JPH05163139A (ja) | 抗動脈硬化剤 | |
RU2004132856A (ru) | Фармацевтический препарат с модифицированным высвобождением | |
JP2004521894A5 (ja) | ||
JP2004528364A5 (ja) | ||
EP2286807A2 (en) | Medicament for preventive and/or therapeutic treatment of adhesion of bowel | |
JP6278417B2 (ja) | ビタミンdとユビキノールの局所用口腔サプリメント組成物 | |
JP2008520709A5 (ja) | ||
JPH01139529A (ja) | 歯周病治療剤及び歯周病治療用組成物 | |
BRPI0716214A2 (pt) | Composições farmacêuticas para o tratamento de infecções fúngicas. | |
JP2002544227A5 (ja) | ||
US20070036849A1 (en) | Use of phospholipid arachidonic acids for increasing muscle mass in humans | |
EP0184471B1 (fr) | Produit comprenant une substance antiprogestomimétique et une substance utérotonique | |
EP1187606A1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
RU2001131557A (ru) | Аналоги витамина D и их фармацевтическое использование | |
WO2001005403A1 (fr) | Medicaments pour soigner les parodontopathies | |
JP4500483B2 (ja) | ヒト由来プロスタグランジン合成酵素阻害剤 | |
JP2008520710A5 (ja) | ||
JP2004506605A5 (ja) |